QYResearch’s new report, Methane Mitigation Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031, highlights that vaccines targeting ruminant methane emissions are transitioning from scientific vision to commercial reality. The market is projected to grow from US$ 62.5 million in 2024 to US$ 150 million by 2031, registering a 13.6% CAGR (2025–2031). Momentum has been reinforced by 2024–2025 breakthroughs, including venture investment into vaccine developers, philanthropic funding from climate foundations, and global buyer demand for scalable Scope 3 emissions reduction in beef and dairy. Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample/3403969 Leading Companies ArkeaBio Lucidome Bio Pasture Biosciences The Pirbright Institute – RVC Consortium AgResearch / NZAGRC Program Applications Cattle Sheep Other Ruminants Classification Vaccines Targeting Methane-producing Archaea Vaccines Modulating Immune Responses Latest Data Forecasted Market Size in 2031: US$ 150 million CAGR (2025–2031): 13.6% Forecast Units: USD million (value) Coverage: Revenue and volume forecast, company share, competitive landscape, growth factors and trends Regions: North America, Europe, Asia Pacific, South America, Middle East & Africa Leading Companies in scope: Lucidome Bio, ArkeaBio Segmentation by Type: Vaccines targeting methanogenic archaea; immune-response-modulating vaccines Segmentation by Application: Cattle, Sheep, Other Ruminants 2024–2025 Updates and Achievements ArkeaBio secured US$ 26.5 million in Series A funding led by Breakthrough Energy Ventures in 2024, accelerating its methane vaccine development with a stated aim to achieve market availability before 2030. The Bezos Earth Fund awarded US$ 9.4 million in 2024 to an international research consortium led by The Pirbright Institute and the Royal Veterinary College, advancing early vaccine prototypes targeting a minimum 30% methane reduction. Lucidome Bio launched in 2024 to commercialize 15 years of New Zealand’s AgResearch/NZAGRC work, focusing on low-cost, pasture-suitable vaccines for multi-ruminant applications. Economic analysis in 2025 proposed an Advance Market Commitment, with US$ 10.32 per dose incentives over 92 million doses, showing a projected benefit-cost ratio above 12:1 and providing a de-risked path to scale. Scientific reviews in late 2024 confirmed antibody stability in the rumen and promising epitope targeting, but noted limited in-vivo data, underlining the early yet strategically critical nature of the field. Product Snapshots ArkeaBio — Methane-Reducing Vaccine for Cattle Uses protein-antigen technology to stimulate salivary antibodies that neutralize methanogens in cattle rumen. Targets abatement cost below US$100 per ton CO₂e. Backed by US$ 26.5 million in 2024, aiming for commercialization before 2030. Lucidome Bio — Multi-ruminant Vaccine Develops a vaccine inducing high-titer salivary antibodies stable in rumen environments. Designed for cattle, sheep, goats, buffalo, and deer. Emphasizes affordability and suitability for pasture-based systems, with commercialization roadmap launched in 2024. Pasture Biosciences — mRNA Methane Vaccine Pioneers mRNA-based vaccines to direct bovine immune responses toward methanogens. Conducting in vitro and in vivo trials since 2023, with the ambition to deliver cost-effective methane reductions across dairy and beef cattle. Pirbright Institute – RVC Consortium — Cattle Methane Vaccine (Proof-of-concept) Funded in 2024 to demonstrate antibody discovery, vaccination timing in calves, and proof-of-mechanism for methane reductions above 30%. Focused on foundational research for later commercialization. AgResearch / NZAGRC Program — Salivary Antibody Vaccine The original New Zealand program underpinning Lucidome Bio’s product. Established stable antibodies against methanogens and identified conserved targets. Ongoing research sets efficacy thresholds at a minimum of 20% reduction in respiration chamber studies. Downstream Customers Arla Foods Fonterra Dairy Farmers of America Nestlé Danone FrieslandCampina Lactalis Saputo Glanbia Yili Group Mengniu Dairy JBS Tyson Foods Marfrig Cargill Market Trend Funding acceleration From 2024 to 2025, funding shifted from small research grants to venture-scale investments. The Bezos Earth Fund and Breakthrough Energy Ventures positioned methane vaccines as a credible solution, while AgriZeroNZ and other farmer-backed groups secured support for pasture systems. Vaccine economics Analyses in 2025 project vaccines at production costs between US$ 1–4 per dose, with abatement below US$100 per ton CO₂e. Advance Market Commitment proposals suggest strong economic returns, reinforcing feasibility for global rollout. Pasture-based adoption Unlike feed additives requiring daily dosing, vaccines fit seamlessly into existing herd health programs. Lucidome Bio and ArkeaBio emphasize calfhood vaccinations and pasture compatibility, critical for regions where intensive feeding is rare. Scientific progress Antibody stability and targeting have advanced significantly, but real-world methane reductions remain limited in published studies. Only a few research groups led the field in 2024, with more entrants emerging in 2025, gradually reducing technical risk. Policy and buyer pull Methane has become a central target in climate strategies. Dairy processors and meatpackers are under growing pressure from Scope 3 emissions reporting. Retailers are testing early pilots, and governments are embedding methane abatement into climate policies, creating early demand signals. Coexistence with other tools Vaccines are viewed as complementary to feed additives, selective breeding, and manure management. The consensus is that a combined portfolio will deliver the largest reductions, aligning with global methane reduction pledges by 2030. Communication and adoption risks Misinformation has surfaced around methane reduction solutions, making transparency critical. Clear safety data and farmer engagement will be key to ensure vaccines are widely accepted and trusted when commercialized. Request for Pre-Order Enquiry On This Report https://www.qyresearch.com/customize/3403969 About us： QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data. Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details. We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers. More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) EN: https://www.qyresearch.com JP: https://www.qyresearch.co.jp